{"id":336770,"date":"2025-11-27T09:00:00","date_gmt":"2025-11-27T08:00:00","guid":{"rendered":"https:\/\/miranza.es\/uncategorized\/una-nueva-opcion-no-quirurgica-podria-marcar-un-antes-y-un-despues-en-el-tratamiento-del-glaucoma\/"},"modified":"2025-11-27T11:37:43","modified_gmt":"2025-11-27T10:37:43","slug":"una-nueva-opcion-no-quirurgica-podria-marcar-un-antes-y-un-despues-en-el-tratamiento-del-glaucoma","status":"publish","type":"post","link":"https:\/\/miranza.es\/en\/news\/una-nueva-opcion-no-quirurgica-podria-marcar-un-antes-y-un-despues-en-el-tratamiento-del-glaucoma\/","title":{"rendered":"A new non-surgical option could mark a turning point in the treatment of glaucoma"},"content":{"rendered":"\n

Vissum Grupo Miranza has Eyetronic technology, which, through electrical stimulation, is able to activate inactive nerve cells in the optic nerve to restore vision<\/strong><\/p>\n\n\n\n

A new step forward in the fight against glaucoma<\/a>. Miranza\u2019s clinic in Alicante has become the first in Spain to incorporate Eyetronic technology, a device that uses non-invasive electrical stimulation to activate inactive nerve cells in the optic nerve of patients with glaucoma.<\/p>\n\n\n\n

This treatment, which is being successfully tested at Vissum Grupo Miranza, aims to improve cellular metabolism, preserve visual function and, in certain cases, recover part of the lost vision.<\/p>\n\n\n\n

According to Dr. Luc\u00eda Rial, glaucoma specialist at Vissum Grupo Miranza<\/strong>, \u201cthe use of Eyetronic changes the concept of a disease that has been considered irreversible until now.\u201d The specialist adds that the technology makes it possible to treat damaged ganglion cells<\/strong> with the goal of improving parameters such as visual field, visual acuity, contrast sensitivity and patients\u2019 quality of life.<\/p>\n\n\n\n

How Eyetronic Works<\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/h2>\n\n\n\n

Eyetronic uses safe, non-invasive electrical stimulation to reactivate inactive nerve cells, helping improve visual function. The device is marketed in Europe with a CE certificate, and it is also beginning to be used in other countries, with several clinical trials underway.<\/p>\n\n\n\n

The effects of the treatment are progressive: although a more complete and accurate assessment is performed after three months, some patients report earlier improvements in visual field and light perception, especially younger individuals.<\/p>\n\n\n\n

The treatment consists of ten consecutive sessions, each lasting between 60 and 90 minutes<\/strong>. This is the first time that some degree of reversibility has been observed in a disease affecting the optic nerve\u2014the nerve that connects the eye to the brain\u2014whose nerve fibers are damaged by glaucoma, causing progressive vision loss that has, until now, been considered irreversible.<\/p>\n\n\n\n

The team applying the treatment, currently in a trial phase at Vissum Grupo Miranza, is made up of two technicians and Dr. Rial, who work together to ensure the correct application of the device (similar to virtual-reality goggles, from which the electrical stimulation of the optic nerve is delivered) and to optimize results.<\/p>\n\n\n\n

<\/p>\n\n\n\n

\n